

Table of Contents

List of Figures.....	8
List of Tables	11
List of Abbreviations	12
List of Symbols.....	15
Preface.....	16
1 Chapter 01: Cancer, its epidemiology, causes & treatment	25
1.1 Introduction.....	25
1.2 Epidemiology.....	27
1.2.1 Incidence.....	29
1.3 Cancer cell biology.....	30
1.4 Hallmarks of Cancer.....	33
1.5 Lung cancer	34
1.5.1 Types of lung cancer.....	35
1.6 Breast Cancer	36
1.7 Cancer treatment and chemotherapy	37
1.8 Limitations of conventional cancer chemotherapy.....	39
1.9 Exploring the potential of natural products-based nanomedicine for cancer therapy	42
1.9.1 Nano drug delivery	42
1.9.2 Advantages of nanocarrier systems	44
1.9.3 Targeted drug delivery.....	45
1.10 Exploring the potential of natural products based semi-synthetic derivatives for cancer therapy.....	49
1.10.1 Structural modification of natural products.....	49
1.10.2 Molecular hybridization approach and its role in enhancing the therapeutic effect of natural products.....	51

2	Chapter 02: Importance of natural product molecules and targeted drug delivery	53
2.1	Natural products as a foundation for drug discovery	53
2.2	Natural product drug discovery	54
2.2.1	Analysis of natural product sources	54
2.3	Nanomedicine based on natural products	55
2.4	Oleanolic Acid (OLA)	56
2.4.1	Physical and Chemical Nature of Oleanolic Acid	57
2.4.2	Occurrences of Oleanolic Acid in Food and Medicinal Plants	57
2.4.3	Extraction, Isolation and Characterization of Oleanolic Acid	57
2.4.4	Anti-Cancer Effects of Oleanolic Acid	59
2.4.5	Problems associated with Oleanolic acid	60
2.5	Asiatic acid (ASA)	62
2.5.1	Natural sources of Asiatic acid	62
2.5.2	Extraction, Isolation and Characterization of Asiatic Acid	63
2.5.3	Anti-Cancer Effects of Asiatic Acid	64
2.6	Nanomedicine in the treatment of non-small cell lung cancer (NSCLC)	67
2.6.1	Albumin (ALB) as a nanocarrier for cancer therapy	68
2.6.2	D- α -tocopheryl polyethylene glycol 1000 succinate (TPGS)	70
2.6.3	Preparation methods of albumin nanoparticles	71
2.7	Targeted delivery of natural compounds for lung cancer therapy	76
2.7.1	EGFR inhibitors	77
2.8	Semi-synthetic modifications of natural products	78
2.8.1	Click chemistry-inspired structural modification of natural products	78
2.8.2	Semi-synthetic modifications of terpenes	80
3	Chapter 03: Isolation of Oleanolic acid and development of its EGFR targeted albumin nanoparticles, and their cytotoxicity and pharmacokinetics evaluation for lung cancer therapy	82
3.1	Objective	82
3.2	Plan of Study	82

3.3	Materials	83
3.4	Methods.....	84
3.4.1	Extraction and isolation of oleanolic acid	84
3.4.2	Molecular Docking Assessment	85
3.4.3	Preparation of TPGS-SA	85
3.4.4	Characterization of TPGS-SA	85
3.4.5	Synthesis of non-targeted and CTX-conjugated OLA-loaded ALB-NPs	86
3.5	Characterization of ALB-NPs.....	87
3.5.1	Surface charge, particle size, and polydispersity index of ALB-NPs	87
3.5.2	FTIR analysis.....	88
3.5.3	X-Ray Diffraction (XRD) studies.....	88
3.5.4	SDS-PAGE analysis	88
3.5.5	Morphological analysis of ALB-NPs	89
3.5.6	Surface chemistry (XPS)	89
3.5.7	Entrapment efficiency.....	90
3.5.8	Thermal analysis of ALB-NPs	91
3.6	<i>In vitro</i> studies	91
3.6.1	<i>In vitro</i> release study.....	91
3.6.2	<i>In vitro</i> hemocompatibility study	92
3.6.3	Cell line maintenance and cell culture growth conditions.....	92
3.6.4	<i>In vitro</i> cytotoxicity study.....	93
3.6.5	Qualitative cellular uptake analysis	93
3.6.6	Quantitative cellular uptake by flow cytometry	94
3.6.7	Apoptosis detection by Acridine orange/ethidium bromide staining	94
3.6.8	ROS generation assay	95
3.6.9	AnnexinV- Alexa Fluor 488/propidium iodide staining assay	96
3.6.10	Cell cycle analysis	96
3.7	<i>In vivo</i> studies	97
3.7.1	Pharmacokinetic study.....	97
3.7.2	Histopathology.....	98
3.7.3	<i>In vivo</i> lung safety study in rats	99

3.7.4	<i>In vivo</i> lung cancer targeting study by ultrasound and photoacoustic study	99
3.8	Statistical analysis	100
3.9	Results and discussion	101
3.9.1	<i>In silico</i> docking	101
3.9.2	Characterization of TPGS-SA	103
3.10	Characterization of Nanoparticles	103
3.10.1	Size, polydispersity, and zeta potential	103
3.10.2	FTIR spectroscopy	104
3.10.3	XRD	105
3.10.4	SDS-PAGE analysis	106
3.10.5	TEM	107
3.10.6	AFM	107
3.10.7	XPS analysis	108
3.10.8	DSC analysis	109
3.10.9	TGA analysis	110
3.10.10	Entrapment Efficiency	111
3.11	<i>In vitro</i> analysis	111
3.11.1	<i>In vitro</i> drug release	111
3.11.2	<i>In vitro</i> hemocompatibility study	111
3.11.3	<i>In vitro</i> cytotoxicity study	112
3.11.4	Qualitative cellular uptake study	114
3.11.5	Quantitative cellular uptake study	114
3.11.6	Apoptosis analysis	115
3.11.7	ROS generation assay	117
3.11.8	Annexin V-Alexa fluor/Propidium iodide staining assay	118
3.11.9	Cell cycle analysis	120
3.12	<i>In vivo</i> studies	120
3.12.1	Pharmacokinetic study	120
3.12.2	Histopathology	122
3.12.3	<i>In vivo</i> safety using bronchoalveolar lavage (BAL) fluids of rats	123
3.12.4	<i>In vivo</i> lung cancer targeting efficacy	125

4 Chapter 04: Isolation of Asiatic acid and rational development of its EGFR targeted albumin nanoparticles, and their cytotoxicity and pharmacokinetics evaluation for lung cancer therapy	127
4.1 Objective	127
4.2 Plan of study	127
4.3 Chemicals and reagents	128
4.4 Methods.....	129
4.4.1 Extraction and isolation of Asiatic acid (ASA).....	129
4.4.2 Molecular docking investigations.....	129
4.4.3 Preparation of TPGS- SA	130
4.4.4 Characterization of TPGS-SA	130
4.4.5 Preparation and optimization of ASA-loaded ALB-NPs	130
4.4.6 CTX conjugation to ASA-ALB-NPs.....	131
4.5 Characterization of the physicochemical properties of ALB-NPs.	132
4.5.1 Assessment of the charge, particle size, and polydispersity index of ALB-NPs. 132	
4.5.2 Fourier Transform Infrared (FTIR) spectroscopy analysis.....	132
4.5.3 X-ray diffraction (XRD) analysis	133
4.5.4 Morphological analysis of ALB-NPs	133
4.5.5 Surface chemistry (XPS) analysis	134
4.5.6 Assessment of entrapment efficiency	134
4.5.7 Thermal analysis of ALB-NPs	135
4.6 <i>In vitro</i> studies	136
4.6.1 <i>In vitro</i> drug release study	136
4.6.2 Cell line maintenance and cell culture growth conditions.....	136
4.6.3 Cell cytotoxicity study.....	136
4.6.4 Cellular uptake of ALB-NPs	137
4.6.5 Apoptosis assay through acridine orange/ethidium bromide dual staining	138
4.6.6 AnnexinV-Alexa Fluor 488/Propidium iodide staining assay.....	139
4.6.7 Cell cycle analysis	139
4.6.8 Pharmacokinetic study.....	140
4.6.9 Histopathology.....	141

4.7	Statistical analysis	142
4.8	Results and discussion	142
4.8.1	<i>In silico</i> docking	142
4.8.2	Characterization of TPGS-SA	144
4.9	NPs characterization.....	145
4.9.1	Size, polydispersity, and zeta potential of NPs	145
4.9.2	FTIR spectroscopy.....	146
4.9.3	XRD analysis.....	147
4.9.4	Morphological Assessment of ALB-NPs	148
4.9.5	DSC analysis.....	149
4.9.6	TGA analysis	150
4.9.7	Entrapment Efficiency	151
4.10	<i>In vitro</i> analysis.....	152
4.10.1	<i>In vitro</i> release of drug from ALB formulations	152
4.10.2	Assessment of <i>in vitro</i> cytotoxicity	152
4.10.3	Investigation of <i>in vitro</i> cellular uptake.....	154
4.10.4	Acridine orange/ethidium bromide staining for detection of apoptosis in A549 cells.....	155
4.10.5	AnnexinV-Alexa fluor/Propidium iodide staining assay.....	158
4.10.6	Cell cycle analysis	159
4.11	<i>In vivo</i> studies	160
4.11.1	Pharmacokinetic Investigation	160
4.11.2	Histopathological evaluation	161
5	Chapter 05: Synthesis and biological evaluation of click chemistry-inspired triazole derivatives of natural product molecules for cancer treatment	164
5.1	Introduction and Objective.....	164
5.1.1	Click chemistry and the pharmacological applications of 1,2,3-Triazoles.	164
5.2	Experimental work	165
5.2.1	Materials	165
5.2.2	General synthetic procedures.....	166

5.2.3	<i>In silico</i> studies	170
5.3	Results and Discussion.....	176
5.3.1	Characterization of synthesized 1,2,3-triazole derivatives	176
5.3.2	<i>In silico</i> studies	187
5.3.3	Biological Activity	191
5.4	Conclusion	194
6	Summary, conclusion and future scope.....	197
7	References.....	207
8	List of publications	219
9	Curriculum Vitae.....	220